BR0214539A - Preventivos ou remédios para doença de alzheimer ou inibidores de fibrose por proteìna amilóide, contendo compostos heteroarìlicos que contêm nitrogênio - Google Patents

Preventivos ou remédios para doença de alzheimer ou inibidores de fibrose por proteìna amilóide, contendo compostos heteroarìlicos que contêm nitrogênio

Info

Publication number
BR0214539A
BR0214539A BR0214539-1A BR0214539A BR0214539A BR 0214539 A BR0214539 A BR 0214539A BR 0214539 A BR0214539 A BR 0214539A BR 0214539 A BR0214539 A BR 0214539A
Authority
BR
Brazil
Prior art keywords
alzheimer
amyloid protein
disease
remedies
fibrosis inhibitors
Prior art date
Application number
BR0214539-1A
Other languages
English (en)
Inventor
Masaki Meguro
Tomiichiro Oda
Yasuhiro Nakagami
Shinji Marumoto
Kazuo Koyama
Isao Kaneko
Original Assignee
Btg Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Btg Int Ltd filed Critical Btg Int Ltd
Publication of BR0214539A publication Critical patent/BR0214539A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/22—Nitrogen and oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/50—Three nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
    • C07D251/18—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/48—Two nitrogen atoms
    • C07D251/52—Two nitrogen atoms with an oxygen or sulfur atom attached to the third ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/54—Three nitrogen atoms
    • C07D251/70—Other substituted melamines

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"PREVENTIVOS OU REMéDIOS PARA DOENçA DE ALZHEIMER OU INIBIDORES DE FIBROSE POR PROTéINA AMILóIDE, CONTENDO COMPOSTOS HETEROARìLICOS QUE CONTêM NITROGêNIO". Descreve-se preventivos ou remédio para doença de Alzheimer, ou inibidores de fibrose por proteína amilóide, que contêm, como ingrediente ativo, compostos que têm a fórmula genérica (I), ou seus sais de uso farmacológico; e derivados heteroarílicos que contêm nitrogênio, tendo substituintes específicos, que são úteis para doença de Alzheimer, ou inibidores de fibrose por proteínas amilóides, ou seus sais de uso farmacológico: onde R^ 1^ e R^ 2^ representam, cada um, H ou alquila; Z^ 1^ e Z^ 2^ representam, cada um, H, alquila, alcóxi, halo-alquila ou halogênio; Z^ 3^ representa alcóxi, SH, alquil-tio, NH~ 2~, mono- ou dialquil-amino, OH ou halogênio; Z^ 4^ e Z^ 5^ representam, cada um, H ou halogênio; e A representa 4,6-pirimidino-1,3-diila, 1,3,5-triazino-2,6-diila, etc.
BR0214539-1A 2001-11-28 2002-11-25 Preventivos ou remédios para doença de alzheimer ou inibidores de fibrose por proteìna amilóide, contendo compostos heteroarìlicos que contêm nitrogênio BR0214539A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2001361847 2001-11-28
JP2002192777 2002-07-02
PCT/JP2002/012265 WO2003045923A1 (en) 2001-11-28 2002-11-25 Preventives or remedies for alzheimer’s disease or amyloid protein fibrosis inhibitors containing nitrogen-containing heteroaryl compounds

Publications (1)

Publication Number Publication Date
BR0214539A true BR0214539A (pt) 2004-11-03

Family

ID=26624724

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0214539-1A BR0214539A (pt) 2001-11-28 2002-11-25 Preventivos ou remédios para doença de alzheimer ou inibidores de fibrose por proteìna amilóide, contendo compostos heteroarìlicos que contêm nitrogênio

Country Status (21)

Country Link
US (6) US7589105B2 (pt)
EP (1) EP1473289B1 (pt)
JP (1) JP4490690B2 (pt)
KR (1) KR101031720B1 (pt)
CN (1) CN100354267C (pt)
AT (1) ATE438629T1 (pt)
AU (1) AU2002349480B2 (pt)
BR (1) BR0214539A (pt)
CA (1) CA2468948C (pt)
DE (1) DE60233266D1 (pt)
DK (1) DK1473289T3 (pt)
ES (1) ES2330090T3 (pt)
HK (1) HK1070371A1 (pt)
HU (1) HUP0402657A3 (pt)
IL (2) IL162210A0 (pt)
MX (1) MXPA04005027A (pt)
NO (1) NO328271B1 (pt)
NZ (1) NZ533147A (pt)
PL (1) PL370531A1 (pt)
TW (1) TW200300688A (pt)
WO (1) WO2003045923A1 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
EP2316459B1 (en) * 2002-07-29 2013-11-06 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds for use in methods of treating or preventing autoimmune diseases
SG176311A1 (en) * 2002-07-29 2011-12-29 Rigel Pharmaceuticals Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
WO2005003103A2 (en) * 2003-06-30 2005-01-13 Astrazeneca Ab 2, 4, 6-tri-substituted 6-membered heterocycles and their use in the treatment of neurodegenerative diseases
CN102358738A (zh) * 2003-07-30 2012-02-22 里格尔药品股份有限公司 2,4-嘧啶二胺化合物及其预防和治疗自体免疫疾病的用途
WO2006068770A1 (en) 2004-11-24 2006-06-29 Rigel Pharmaceuticals, Inc. Spiro-2, 4-pyrimidinediamine compounds and their uses
CA2591948C (en) 2005-01-19 2013-11-12 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US20070135437A1 (en) * 2005-03-04 2007-06-14 Alsgen, Inc. Modulation of neurodegenerative diseases
JP2008531710A (ja) * 2005-03-04 2008-08-14 アルスジエン・インコーポレーテツド 神経変性疾患の調節
US20060270694A1 (en) * 2005-05-03 2006-11-30 Rigel Pharmaceuticals, Inc. JAK kinase inhibitors and their uses
GB0608386D0 (en) 2006-04-27 2006-06-07 Senexis Ltd Compounds
US7989465B2 (en) 2007-10-19 2011-08-02 Avila Therapeutics, Inc. 4,6-disubstituted pyrimidines useful as kinase inhibitors
US7982036B2 (en) * 2007-10-19 2011-07-19 Avila Therapeutics, Inc. 4,6-disubstitued pyrimidines useful as kinase inhibitors
US8393968B2 (en) * 2008-09-03 2013-03-12 Igt Gaming system, gaming device and method for providing a strategy game having a plurality of awards
US8210935B2 (en) * 2008-11-12 2012-07-03 Igt Gaming system, gaming device and method of providing collectors and tokens associated with collectors
US8287364B2 (en) * 2008-11-13 2012-10-16 Igt Gaming system, gaming device, and method for providing a game in which a player collects emblems by positioning accumulators in a field
KR101095026B1 (ko) * 2009-01-23 2011-12-20 한국과학기술연구원 비스(스티릴)피리미딘 및 비스(스티릴)벤젠 유도체, 이의 약학적으로 허용 가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 베타아밀로이드 집적 관련 질환의 예방 또는 치료용 약학적 조성물
CN102706839B (zh) * 2011-01-31 2015-08-12 香港科技大学 水溶性aie发光剂及其在检测和延迟淀粉样蛋白质的淀粉样纤维化中的用途
IN2014MN00381A (pt) * 2011-08-04 2015-06-19 Colourtex Ind Ltd
JP6668329B2 (ja) 2015-03-25 2020-03-18 国立研究開発法人国立長寿医療研究センター 新規オキサジアゾール誘導体及びこれを含有する医薬
WO2017106367A1 (en) * 2015-12-15 2017-06-22 D.E. Shaw Research, Llc Method of treating neurodegenerative disorders by rescuing alpha-synuclein toxicity

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2393755A (en) * 1942-08-05 1946-01-29 Gen Electric Method of preparing hydroxyarylamino triazines
GB9325217D0 (en) 1993-12-09 1994-02-09 Zeneca Ltd Pyrimidine derivatives
FR2720638B1 (fr) * 1994-06-03 1997-04-04 Oreal Compositions cosmétiques antisolaires à base d'un mélange synergétique de filtres et utilisations.
GB9523675D0 (en) * 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
CA2291710A1 (en) * 1997-05-22 1998-11-26 Tatsuya Tamaoki Bisaryl compounds and cancer remedies containing the same
US6335339B1 (en) * 1998-01-13 2002-01-01 Scriptgen Pharmaceuticals, Inc. Triazine antiviral compounds
ES2274634T3 (es) 1998-08-29 2007-05-16 Astrazeneca Ab Compuestos de pirimidina.
ES2270612T3 (es) * 1998-08-29 2007-04-01 Astrazeneca Ab Compuestos de pirimidina.
MXPA02003436A (es) 1999-10-07 2002-08-20 Amgen Inc Inhibidores de triazina cinasa.
WO2001055093A1 (fr) * 2000-01-25 2001-08-02 Japan Tobacco Inc. Composes a base de n-arylhydrazide et leur utilisation en tant que medicaments
JP2002145840A (ja) * 2000-01-25 2002-05-22 Japan Tobacco Inc Ｎ−アリールヒドラジド化合物及びその医薬用途
GB0428082D0 (en) * 2004-12-22 2005-01-26 Welcome Trust The Ltd Therapeutic compounds

Also Published As

Publication number Publication date
HK1070371A1 (en) 2005-06-17
US20110275641A1 (en) 2011-11-10
TW200300688A (en) 2003-06-16
CN100354267C (zh) 2007-12-12
US20090286794A1 (en) 2009-11-19
IL162210A0 (en) 2005-11-20
EP1473289A4 (en) 2005-11-23
ES2330090T3 (es) 2009-12-04
HUP0402657A2 (hu) 2005-03-29
US20090286809A1 (en) 2009-11-19
PL370531A1 (en) 2005-05-30
ATE438629T1 (de) 2009-08-15
CN1596246A (zh) 2005-03-16
NO328271B1 (no) 2010-01-18
EP1473289B1 (en) 2009-08-05
DE60233266D1 (de) 2009-09-17
JPWO2003045923A1 (ja) 2005-04-07
KR101031720B1 (ko) 2011-04-29
WO2003045923A1 (en) 2003-06-05
US20110275640A1 (en) 2011-11-10
EP1473289A1 (en) 2004-11-03
US20050054732A1 (en) 2005-03-10
KR20040068170A (ko) 2004-07-30
NO20042709L (no) 2004-08-27
CA2468948A1 (en) 2003-06-05
US7589105B2 (en) 2009-09-15
MXPA04005027A (es) 2004-08-11
HUP0402657A3 (en) 2010-03-29
US8003645B2 (en) 2011-08-23
AU2002349480A1 (en) 2003-06-10
DK1473289T3 (da) 2009-11-30
CA2468948C (en) 2012-04-17
IL162210A (en) 2012-08-30
NZ533147A (en) 2006-12-22
US20080182846A1 (en) 2008-07-31
JP4490690B2 (ja) 2010-06-30
AU2002349480B2 (en) 2008-10-30

Similar Documents

Publication Publication Date Title
BR0214539A (pt) Preventivos ou remédios para doença de alzheimer ou inibidores de fibrose por proteìna amilóide, contendo compostos heteroarìlicos que contêm nitrogênio
BR0116063A (pt) Inibidores de sulfonamida heterocìclica da produção de beta amilóide e seus usos
BR0109703A (pt) Derivados de piperazina
DE60210944D1 (de) N-substituierte heterocyclische nichtaryl-nmda/nr2b-antagonisten
TR200201205T2 (tr) N-ikame edilmiş karbamoiloksialkil-azolyum türevleri.
BR0211805A (pt) Herbicidas
DK0880508T3 (da) Quinazolinderivater som VEGF-inhibitorer
DK0622361T3 (da) Heterocykliske forbindelser som bradykininantagonister
MXPA03011039A (es) Nuevos compuestos heterociclicos, su preparacion y uso como medicamentos, particularmente como agentes anti-bacterianos.
TR200201505T2 (tr) Terapötik maddeler olarak pirazolopirimidinler
YU6303A (sh) Nova heterociklična jedinjenja, njihovo dobijanje i njihova upotreba kao medikamenata, a naročito kao anti-bakterijskih agenasa
BR0214891A (pt) Herbicidas
BR0206433A (pt) Composto, composição farmacêutica, processo para a prepapação de um composto, e, uso de um composto
NO20014479D0 (no) Fremgangsmåte ved behandling av spiseforstyrrelser
GB0124933D0 (en) Chemical compounds
CY1106522T1 (el) Ετepοκυκλικη ενωση και αντικαρκινικο μεσο που πepιεχει την ιδια ως δραστικο συστατικο
HK1048474B (zh) 取代的噻吩-3-基磺酰基氨基(硫代)羰基三唑啉(硫)酮類化合物
TR200002605T2 (tr) Nitrik oksit sentaz inhibitörleri olarak faydalı halojene amidino amino asit türevleri
DE60116589D1 (de) Fungizide Phenylamidinderivative
ATE300541T1 (de) Pyrazolopyridinderivate
BR0210531A (pt) Derivados de ácido sulfÈnico
TR200200100T2 (tr) Kristalin 1-metilkarbapenem türevleri.
BR0114159A (pt) Herbicidas de fenilpropiniloxipiridina
BRPI0407841A (pt) inibidores heterocìclicos de quinase
DK0870763T3 (da) Kondenserede piperidinderivater som inhibitorer for syntese af nitrogenmonoxid

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B25G Requested change of headquarter approved

Owner name: BTG INTERNATIONAL LIMITED (GB)

Free format text: ENDERECO DO DEPOSITANTE ALTERADO CONFORME SOLICITADO NA PETICAO NO 020110103158/RJ DE 04/10/2011.

B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements